Skip to main content

Month: August 2020

Goodfood réalise son placement public d’actions ordinaires par voie de prise ferme annoncé précédemment et annonce l’exercice intégral de l’option de surallocation pour un placement total de 40 M$

NE PAS DISTRIBUER AUX AGENCES DE PRESSE DES ÉTATS-UNIS NI DIFFUSER AUX ÉTATS‑UNIS.MONTRÉAL, 05 août 2020 (GLOBE NEWSWIRE) — Marché Goodfood Corp. (« Goodfood » ou la « Société ») (TSX : FOOD), un chef de file canadien de l’épicerie en ligne, a le plaisir d’annoncer la clôture de son placement public par voie de prise ferme annoncé précédemment (le « placement »), aux termes duquel un syndicat de prise ferme mené conjointement par Desjardins Marché des capitaux et Stifel GMP (collectivement, les « preneurs fermes co-chefs de file »), et comprenant Financière Banque Nationale Inc., Scotia Capitaux Inc., Raymond James Ltée, RBC Dominion valeurs mobilières Inc., Corporation Canaccord Genuity, Eight Capital et Acumen Capital Finance Associés Limitée (collectivement avec les preneurs fermes co-chefs de file, les « preneurs fermes ») ont...

Continue reading

Verizon Ventures leads €4 Million Series A financing round in PICadvanced

BASKING RIDGE, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) — Verizon Ventures today announced it led a €4 million ($4.5 million) Series A financing round in PICadvanced (PICa), a developer of cost-effective optics and photonics solutions for telecom applications. Joining Verizon Ventures in the round is a 200M Co-investment Fund managed by PME Investimentos, which makes co-investments in high-growth Portuguese startups. Founded in 2014 and based in Ílhavo, Portugal, PICa has been active in the development of optoelectronic transceivers for a new telecommunications network standard called NG-PON2 (Next-Generation Passive Optical Network 2). Leveraging its expertise, the company aims to provide innovative solutions for the Passive Optical Network (PON) market. It has solved many complex problems through optics, from design and development...

Continue reading

CV Sciences, Inc. Announces Launch of Happy Lane™ CBD Product Line

SAN DIEGO, Aug. 05, 2020 (GLOBE NEWSWIRE) — CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced the launch of its new Happy Lane™ CBD product line.Happy Lane™ non-GMO, hemp derived CBD products are manufactured with 0.00% THC (“THC-free”) and formulated using CV Sciences’ rigorous standards for quality, verified by a third party laboratory for purity, strength and composition.Leveraging the success of the Company’s top selling PlusCBD™ product line, CV Sciences plans to make Happy Lane™ broadly available to U.S. consumers through new distribution channels, including the $650 billion convenience store channel.Happy Lane™ is now available at select natural products retailers nationwide in six product SKUs and multiple form...

Continue reading

Net Element Enters Definitive Merger Agreement with Electric Vehicle Company Mullen Technologies

MIAMI, Aug. 05, 2020 (GLOBE NEWSWIRE) — via NetworkWire — Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”) today announced the execution of a definitive agreement to merge with privately-held Mullen Technologies, Inc. (“Mullen”), a Southern California-based electric vehicle company, in a stock-for-stock reverse merger in which Mullen’s stockholders will receive a majority of the outstanding stock in the post-merger Company.Highlighted Terms of the Definitive Merger Agreement:Under the terms of the agreement, Net Element’s wholly owned, newly formed subsidiary will acquire all the outstanding shares of Mullen.  Upon completion of the merger, Net Element shareholders will own 15% and Mullen shareholders will own 85% of the issued and outstanding shares of the combined Company.  Net Element has the right to acquire...

Continue reading

Algernon Announces First Patient Dosed in Phase 2 IPF and Chronic Cough Human Trial of Ifenprodil

VANCOUVER, British Columbia, Aug. 05, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that the first patient has been dosed in its Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough clinical study of its re-purposed drug NP-120 (Ifenprodil). The patient was enrolled and dosed at the Waikato Hospital located in Hampton, New Zealand.Phase 2 Study Summary:The purpose of this proof-of-concept Phase 2 human trial is to determine the efficacy of Ifenprodil in the preservation of lung function in IPF patients (including biomarkers of fibrosis) and its associated cough. There are 5 sites in total participating in the study with 3 located in Australia and 2 in New Zealand.Ifenprodil...

Continue reading

Weyland Tech Sets Second Quarter 2020 Earnings Conference Call for Friday, August 14, 2020 at 11:00 a.m. ET

NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) — Weyland Tech, Inc. (OTCQX: WEYL), a leading global provider of eCommerce, mCommerce, and fintech business enablement solutions, will hold a conference call on Friday, August 14, 2020 at 11:00 a.m. Eastern time to discuss results for the second quarter ended June 30, 2020. The financial results will be issued in a press release prior to the call.Weyland management will host the call, followed by a question and answer period.Date: Friday, August 14, 2020Time: 11:00 a.m. Eastern time (8:00 a.m. Pacific time)Toll-free dial-in number: 1-866-548-4713International dial-in number: 1-323-794-2093Conference ID: 5079047Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the...

Continue reading

ElectraMeccanica Names Three Finalist States in BDO-Led Search for SOLO EV U.S. Assembly Facility and Engineering Technical Center

VANCOUVER, British Columbia, Aug. 05, 2020 (GLOBE NEWSWIRE) — ElectraMeccanica Vehicles Corp. (NASDAQ: SOLO) (“ElectraMeccanica” or the “Company”), a designer and manufacturer of electric vehicles including the single-occupant, three-wheeled SOLO EV, today provided an update related to its ongoing search for the Company’s future U.S. based assembly facility and engineering technical center.Since late February, the Company has been engaged with BDO USA’s Site Selection & Business Incentives Practice (“BDO”) in a nationwide review of potential locations that matched ElectraMeccanica’s criteria. BDO initially identified seven candidates and sent initial requests for proposal to the chief economic development entities in each state. Earlier in June, the Company narrowed the candidate list to five.Following...

Continue reading

IEC Announces Fiscal 2020 Third Quarter Results

REVENUE OF $47.4 MILLION; UP 17% YEAR OVER YEARGROSS MARGIN OF 14%GENERATED $6.0 MILLION OF OPERATING CASH FLOWNEWARK, N.Y., Aug. 05, 2020 (GLOBE NEWSWIRE) — IEC Electronics Corp. (Nasdaq: IEC) today announced results for the fiscal 2020 third quarter and nine months ended June 26, 2020.IEC reported revenues of $47.4 million for the third quarter of fiscal 2020, an increase of 17% as compared to revenues of $40.3 million for the third quarter of the year ended September 30, 2019 (“fiscal 2019”) and a sequential increase of 7% compared to revenues of $44.2 million in the second quarter of fiscal 2020. Gross profit for the third quarter of fiscal 2020 was $6.6 million, or 14% of sales, compared to gross profit of $5.6 million, or 13.9% of sales in the third quarter of fiscal 2019. Selling and administrative expenses were $3.7 million...

Continue reading

Bellerophon Provides Clinical Program Update and Reports Second Quarter 2020 Financial Results

WARREN, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2020.“Bellerophon has achieved significant clinical and regulatory progress advancing our development program for the INOpulse® inhaled nitric oxide therapy,” said Fabian Tenenbaum, Chief Executive Officer of Bellerophon. “We are pleased to have treated the first patient with INOpulse in our COViNOX Phase 3 clinical trial for the treatment of COVID-19 and are excited to work with leading hospitals across the U.S. to enroll patients as expeditiously as possible. The trial initiation...

Continue reading

Hudson Global Reports 2020 Second Quarter Results

OLD GREENWICH, Conn., Aug. 05, 2020 (GLOBE NEWSWIRE) — Hudson Global, Inc. (Nasdaq: HSON), a leading global total talent solutions company, announced today financial results for the second quarter ended June 30, 2020.2020 Second Quarter SummaryRevenue of $24.6 million decreased 7.0% from the second quarter of 2019 (3.0% in constant currency).Adjusted net revenue of $8.9 million decreased 23.4% from the second quarter of 2019 (21.3% in constant currency).Net loss improved to $0.8 million, or $0.27 per basic and diluted share, from a net loss of $0.9 million, or $0.29 per basic and diluted share, for the second quarter of 2019.  Adjusted net loss per diluted share (Non-GAAP measure)* was $0.13 versus $0.07 in the second quarter of 2019.Adjusted EBITDA (Non-GAAP measure)* loss was $0.4 million compared to adjusted EBITDA of $0.3 million...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.